Professor David Sinclair, a genetics professor at the Blavatnik Institute, announced that next month will see the beginning of the first human clinical trial to test the possibility of reversing or slowing the aging process and treating related diseases. He described this step as a "historic moment in human medicine." Speaking at the World Government Summit, Sinclair stated, "We need to address all diseases at once, and that means aging, because aging is the cause of these diseases." He emphasized that this technology could extend people's lives to be longer, healthier, and more productive, thereby redefining aging and transforming it from a period of decline into a time when one can maintain vitality and activity even into their eighties and nineties. Sinclair also pointed out that using the three Yamanaka genes allows for the rejuvenation of cells by up to 75% within 6 weeks, without the risk of creating cancerous cells. Previous experiments on animals have demonstrated the ability to regenerate tissues and repair optic nerves, leading to the curing of blindness in mice, as well as treating diseases of the brain, liver, and kidneys. "Yamanaka genes" are four transcription factors (Oct4, Sox2, Klf4, c-Myc) discovered by scientist Shinya Yamanaka in 2006, and they are used to reprogram adult, differentiated cells into a state similar to embryonic stem cells (induced pluripotent stem cells, iPSCs). This discovery enables tissue regeneration, reversing aging, and treating diseases.
